United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Theriva Biologics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -137.82% | -676.37% | 117.32% | 53.97% | 35.05% | 25.98% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -64.52% | -74.88% | -94.24% | -94.2% | -94.18% | -94.3% |
| Total Assets | $38,239.00K | $25,183.00K | $25,183.00K | $25,183.00K | $25,183.00K | $25,183.00K |
| Sector average | $3,280,499.23K | $3,298,345.31K | $3,676,894.01K | |||
| Net Income | -$23,739.00K | -$23,744.76K | -$23,732.12K | -$23,721.29K | -$23,718.13K | -$23,748.02K |
| $4,262,561.28K |
| $4,994,412.92K |
| $5,761,557.24K |